Immune pharmaceutical has been violating the us bankruptcy code and only delay delay and increasing legal expenses and administrative expenses. The us trustee might get more value out of the assets of immune pharmaceutical and maybe go after managment and board of directors for violating their fiduciary responsibility. US Trustee at one time ask for the conversion but immune pharmaceutical filed to become in compliance.
News 
Market Data 
Discover 
AI
